In a move to increase transparency within the industry, pharmaceutical companies have published the aggregate totals of any payments made last year to healthcare professionals. In accordance with the amendment of the Association of British Pharmaceutical Industry’s (ABPI) Code of Practice last year, ABPI members have disclosed the total amounts given to NHS staff to attend medical education events, support training and development, as well as fees for services such as speaking engagements and participation on advisory boards. They have also disclosed all the payments made to healthcare organisations in terms of grants and donations.
Figures show that payments from the pharmaceutical industry working with healthcare professionals are estimated to be around £40m for 2012. The numbers of health professionals who have received payments will also be revealed, according to the industry.
Much collaborative work takes place between healthcare professionals and the pharmaceutical industry, which is seen as a positive driving force for advancements in patient care and progress in modern medicine. However, it is now recognised that these relationships must remain transparent to maintain integrity and ensure companies’ reputations are not called into question.
Leaders from the medical and pharmaceutical industries are now examining a proposal that in the future, doctors and other healthcare professionals who are paid by drug companies should declare their dealings on a public register. Industry itself has committed to disclose certain payments made to healthcare professionals at an individual level across Europe by 2016 (for payments made in 2015 onwards).
BMI SYSTEM’s tailor-made NAYA software solution can provide the ideal platform for recording any data linked to payments to healthcare professionals and healthcare organisations. According to Laurent Clerc, Regulatory Affairs Expert, “The disclosure of payments is a step forward to increasing transparency in the industry: BMI SYSTEM can take companies one step further however, by providing software that can quickly and easily store any information relating to payments ensuring that companies remain compliant at all times with the ABPI and EFPIA codes.” The NAYA platform has been developed specifically for the pharmaceutical industry and alongside data on compliance; it is able to integrate information on governance and risk management providing a complete solution for any organisation.